Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuko Mishima

Showing results (71-80 of 107) with videos related to

Pageof 11
Sort By:
Leukemia & Lymphoma|November 1, 2011
High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisoneKazuhito Suzuki, Yasuhito Terui, Kenji Nakano, et al.
Coronary Artery Disease|February 24, 2012
Analytical evaluation of plasma serotonin and sphingosine 1-phosphate and their clinical assessment in early atherosclerosisTomonori Sugiura, Yasuaki Dohi, Sumiyo Yamashita, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 31, 2003
[Simultaneous detection of both non-Hodgkin's lymphoma cells and breast cancer cells in pleural effusion--a case report]Eijiro Nagasaki, Noriyuki Furuta, Eiji Shinozaki, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|December 4, 2014
Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractorinessYuko Mishima, Nelson H Tsuno, Mika Matsuhashi, et al.
International Journal of Clinical Oncology|January 12, 2026
Efficacy and safety of subcutaneous mosunetuzumab in combination with lenalidomide and as a monotherapy in Japanese patients with relapsed/refractory follicular lymphomaShinichi Makita, Koji Izutsu, Yuko Mishima, et al.
Cancer Science|December 22, 2005
Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximabYasuhito Terui, Takuma Sakurai, Yuko Mishima, et al.
International Journal of Hematology|September 15, 2022
Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 studyHideki Goto, Koji Izutsu, Daisuke Ennishi, et al.
Annals of Hematology|February 21, 2022
Durable response of therapy-related MDS/AML with concomitant Waldenström's macroglobulinemia treated with venetoclax and azacitidineMitsuhito Hirano, Mikako Tamba, Norihito Inoue, et al.
International Journal of Clinical Oncology|December 9, 2024
Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1Hideki Goto, Takahiro Kumode, Yuko Mishima, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|March 30, 2025
Impact of NRAS mutation on efficacy of triplet induction therapy in newly diagnosed multiple myelomaYuko Mishima, Yuko Shirouchi, Tomoko Takayama, et al.
Pageof 11

Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
Leukemia & Lymphoma|November 1, 2011
High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisoneKazuhito Suzuki, Yasuhito Terui, Kenji Nakano, et al.
Coronary Artery Disease|February 24, 2012
Analytical evaluation of plasma serotonin and sphingosine 1-phosphate and their clinical assessment in early atherosclerosisTomonori Sugiura, Yasuaki Dohi, Sumiyo Yamashita, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 31, 2003
[Simultaneous detection of both non-Hodgkin's lymphoma cells and breast cancer cells in pleural effusion--a case report]Eijiro Nagasaki, Noriyuki Furuta, Eiji Shinozaki, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|December 4, 2014
Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractorinessYuko Mishima, Nelson H Tsuno, Mika Matsuhashi, et al.
International Journal of Clinical Oncology|January 12, 2026
Efficacy and safety of subcutaneous mosunetuzumab in combination with lenalidomide and as a monotherapy in Japanese patients with relapsed/refractory follicular lymphomaShinichi Makita, Koji Izutsu, Yuko Mishima, et al.
Cancer Science|December 22, 2005
Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximabYasuhito Terui, Takuma Sakurai, Yuko Mishima, et al.
International Journal of Hematology|September 15, 2022
Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 studyHideki Goto, Koji Izutsu, Daisuke Ennishi, et al.
Annals of Hematology|February 21, 2022
Durable response of therapy-related MDS/AML with concomitant Waldenström's macroglobulinemia treated with venetoclax and azacitidineMitsuhito Hirano, Mikako Tamba, Norihito Inoue, et al.
International Journal of Clinical Oncology|December 9, 2024
Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1Hideki Goto, Takahiro Kumode, Yuko Mishima, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|March 30, 2025
Impact of NRAS mutation on efficacy of triplet induction therapy in newly diagnosed multiple myelomaYuko Mishima, Yuko Shirouchi, Tomoko Takayama, et al.
Pageof 11